374Water Inc. Form 10-Q Summary
Business context and reporting period
374Water Inc. filed an unaudited Form 10-Q for the quarter and six months ended June 30, 2022. The company develops and commercializes AirSCWO supercritical water oxidation systems intended to recover resources from waste and support clean-water applications. The company sold its first AirSCWO system to Orange County Sanitation District in February 2022. It is a smaller reporting company and emerging growth company listed on Nasdaq under SCWO.
Key financial metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $1.03 million, versus $14,600 | $1.30 million, versus $14,600 |
| Gross profit | $128,020, versus $14,600 | $153,265, versus $14,600 |
| Gross margin | 12.4%, versus 100.0% | 11.8%, versus 100.0% |
| Operating loss | $(1.21) million, versus $(1.87) million | $(2.09) million, versus $(1.94) million |
| Net loss | $(1.21) million, versus $(1.87) million | $(2.09) million, versus $(1.94) million |
| Net margin | (117.8)%, versus not meaningful | (160.1)%, versus not meaningful |
| Operating cash flow | Not separately disclosed | $(1.02) million, versus $(472,286) |
- Cash was $3.10 million at June 30, 2022, compared with $11.13 million at December 31, 2021.
- Marketable securities totaled $6.99 million at fair value, consisting primarily of U.S. Treasury securities. Cash and marketable securities totaled approximately $10.06 million.
- Working capital was $9.43 million, compared with $11.26 million at December 31, 2021.
- Total assets were $11.90 million and total liabilities were $1.43 million. The filing does not report outstanding debt or borrowings.
- Accounts payable and accrued expenses were $682,633, and deferred revenue was $732,620.
- Common shares outstanding were 126,680,895 as of June 30 and August 4, 2022. Basic and diluted loss per share was $(0.01) for the quarter and $(0.02) for the six-month period.
Material changes versus the prior comparable period
- Revenue increased substantially because the company recognized revenue from its first AirSCWO system; prior-period revenue primarily reflected testing, consulting and advisory services.
- Cost of goods sold was $902,508 in the second quarter and $1.15 million for the six-month period, producing low double-digit gross margins.
- Second-quarter operating expenses declined to $1.34 million from $1.89 million, largely because the prior-year period included $1.40 million of product-development expense related to a warrant issuance.
- Six-month operating expenses increased to $2.24 million from $1.96 million. Research and development increased to $608,348 from $153,860, general and administrative expense increased to $641,067 from $63,785, and professional fees increased to $291,760 from $160,638.
- Operating cash use increased to $1.02 million from $472,286 for the six-month comparison, despite the increase in revenue.
- The company purchased approximately $7.00 million of marketable securities during the first six months of 2022, which was the principal reason for the $8.03 million decline in cash.
- All remaining Series D preferred stock was converted into 1,363,149 common shares in January 2022; no preferred shares were outstanding at June 30, 2022.
- Stock-based compensation increased to $236,470 from $25,567 for the six-month period. There were 13.18 million stock options and 1.25 million warrants outstanding at June 30, 2022.
Guidance, outlook, risks and unusual items
- No quantitative revenue, earnings or production guidance is provided. Management stated that available cash and marketable securities should satisfy financial obligations for at least the next 12 months from the report date.
- The company remains development- and commercialization-stage, with revenues concentrated in the first AirSCWO system and related services. Deferred revenue of $732,620 represents amounts billed or received before revenue recognition, with the company expecting 100% of sales-related deferred revenue to be realized within one year.
- Key risks include limited operating history, dependence on successful commercialization of AirSCWO systems, research and development execution, customer concentration, competition, patent and licensing matters, regulatory and economic conditions, interest-rate and market fluctuations, and the need for future capital if cash generation does not improve.
- The company has a worldwide technology license from Duke University. Royalty payments are triggered by licensed product sales and sublicensing fees, and the company must reimburse ongoing patent expenses.
- The company incurred $551,581 of related-party manufacturing expenses through June 30, 2022 and accrued $25,000 of related-party manufacturing expenses at quarter-end.
- Management concluded that disclosure controls and internal control over financial reporting were effective as of June 30, 2022. A previously identified material weakness relating to entity-level controls, including the board and audit committee structure, was reported as remediated after June 2022 board and committee appointments.
- No legal proceedings, defaults on senior securities, or unregistered equity sales were reported in Part II of the filing.
Important facts for investors to verify
- Verify the timing, remaining performance obligations, costs and cash collection associated with the first AirSCWO system and the $732,620 deferred-revenue balance.
- Assess whether the company can improve gross margins from approximately 12% while scaling production and commercialization.
- Reconcile cash usage, Treasury investments and the stated 12-month liquidity assessment against projected operating and capital expenditures.
- Review the concentration of revenue in the first system sale and the pipeline of additional customer contracts.
- Evaluate related-party manufacturing arrangements, pricing, accrued amounts and governance safeguards.
- Track dilution risk from 13.18 million outstanding options, 1.25 million warrants and future financing needs.
- Confirm the status of the Duke license, royalty obligations, patent expenses and protection of the underlying SCWO technology.